Louisiana State University Health New Orleans, an NCI-NCORPS designated institution, and ConcertAI, LLC have formed a five-year partnership to improve the diversity of clinical trials and ensure broader clinical trial access throughout the Gulf South region.
Investigator-initiated EFTISARC-NEO phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus Keytruda (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma has met its primary endpoint.
